An appreciation from the out-going editor-in-chief
- PDF / 381,459 Bytes
- 2 Pages / 595.276 x 790.866 pts Page_size
- 0 Downloads / 166 Views
EDITORIAL
An appreciation from the out‑going editor‑in‑chief Seigo Kinuya1 Published online: 22 November 2019 © The Japanese Society of Nuclear Medicine 2019
Introduction Annals of Nuclear Medicine (ANM), an official journal of the Japanese Society of Nuclear Medicine (JSNM), was launched in September, 1987 by the then board of directors with Professor Kinichi Hisada as the president. These predecessors endeavored to make ANM an international journal by eliminating all Japanese language from it. Now, ANM is recognized worldwide as an international platform for presenting top research results, highlighted by the fact that approximately 70% of submissions currently come from countries other than Japan. An impact factor of 0.503 was first assigned for ANM in 2001, and has steadily increased to 1.648 for the most recent one. I joined the editorial board in November 2006, was promoted to editor-in-chief in November 2009, and have held this position for the subsequent 10 years. I had a pleasant surprise when I looked into the list of articles in 2018. A total of 63% of articles published in that year came from abroad in contrast to 31% in 2009. This particular fact made me realize that the editorial approach of my predecessors was well justified. For this and other reasons, I sincerely appreciate the key role assumed by Prof. Hisada in the very early stage of ANM and for yearly donating the best paper award of ANM, the Hisada Prize, for many years. I am very proud of being one of his former students at the Department of Nuclear Medicine, Kanazawa University. Reflecting on the changes occurring in nuclear medicine throughout the world, the topics of the articles published in ANM have also been changing. Ten years ago, we had a considerable number of articles on conventional single-photon studies including 67Ga/201Tl/99mTc-sestamibi tumor scintigraphy, renal/bone/pulmonary scintigraphy, leukocyte scintigraphy, and so on. Many FDG studies were also published,
* Seigo Kinuya anm‑[email protected]‑u.ac.jp 1
Department of Nuclear Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
but it appeared to me as the dawn of a wide application of clinical PET. Against this background, reimbursement by health insurance of FDG PET for oncologic use was started in 2010 in Japan. In 2018, close to 30% of articles focused on oncology PET, mostly on FDG and several on other relatively new tracers. In the era of theranostics, papers in this regard have become common in ANM, comprising 25% of the total including 68 Ga/99mTc/90Y/177Lu-DOTATATE/DOTATOC/ HYNIC-TOC [1–10], 18F/68 Ga/177Lu-PSMA [3, 4, 7–9], and a new target, CXCR-4 [11]. Phase I/IIa clinical trial of 89 Zr-anti-PSMA minibody was reported by a Japanese group [12]. To promote the proper uses of 177Lu-DOTATATE, JSNM released a manual containing necessary guidelines [1]. Several Japanese institutions are keen to perform boron neutron-capture therapy [13, 14]. The data of most clinical articles were being obtained by dedicated PET or SPECT when I j
Data Loading...
